Notably, emodin has been shown to downregulate androgen receptor (AR) and inhibit prostate cancer growth [5], suggesting that there is a connection between anthraquinone derivatives and steroid receptor in hormone-related cancers. The gene discussed is AR; the disease is Familial prostate cancer.